Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

Sep 20 2016

• By Derrick Gingery

Related Content

Pediatric Rare Disease Voucher Program Faces Expiration

Sep 11 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community

May 25 2016

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

Related Companies

Sarepta Therapeutics, Inc.

Gilead Sciences, Inc.

AbbVie Inc.

Additional Topics

United States Approvals Drug Review Pricing Strategies Regulation Commercial BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window